NCT06907511 - Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older | Biotech Hunter

Enrollment

240

Participants

Timeline

Start Date

April 17, 2025

Primary Completion Date

May 28, 2026

Study Completion Date

May 28, 2026

Conditions

Pandemic Influenza ImmunizationHealthy Volunteers

Interventions

BIOLOGICAL

Pandemic flu H5 HA mRNA SD2 vaccine

"Pharmaceutical Form:~Suspension in a vial~Route of Administration:~Intramuscular injection"

OTHER

Placebo

"Pharmaceutical Form:~Liquid solution in a vial~Route of Administration:~Intramuscular injection"

Trial Locations (13)

Charlottesville Medical Research- Site Number : 8400005, Charlottesville

Coastal Carolina Research Center - North Charleston- Site Number : 8400001, North Charleston

Accel Research Sites Network - DeLand Clinical Research Unit- Site Number : 8400002, DeLand

Accel Research Sites Network - Largo- Site Number : 8400004, Largo

Accel Research Sites - Lakeland Clinical Research Unit- Site Number : 8400006, Lakeland

Velocity Clinical Research - Springdale- Site Number : 8400010, Cincinnati

QUEST Research Institute- Site Number : 8400014, Bingham Farms

Velocity Clinical Research - Omaha- Site Number : 8400012, Omaha

Velocity Clinical Research - Norfolk- Site Number : 8400015, Norfolk

Olympus Clinical Research - Sugar Land- Site Number : 8400009, Sugar Land

Velocity Clinical Research - Salt Lake City- Site Number : 8400011, West Jordan

Velocity Clinical Research - San Diego- Site Number : 8400013, La Mesa

Accel Research Site - NeuroStudies.net, LLC - ERN - PPDS- Site Number : 8400003, Decatur